BioWorld

April 29, 2002

FDA Nixes Cellegy Pain Drug; Stock Takes Half-Off Nosedive

Cellegy Pharmaceuticals Inc.’s stock tumbled more than 50 percent on news that the company is withdrawing the new drug application for Cellegesic, its nitroglycerin ointment for the treatment of pain from anal fissures. (BioWorld Today) Read More

Senators Want To Close Gaps In Generic Drug Legislation

Hirschsprung Disease Gene Find Is First Complete Dissection Of Multifactorial Genetic Disorder

IDEC, Seikagaku Add $34M Extension To IDEC-152 Deal

Other News To Note

BIO Names Specter, Harkin Top Legislators Of The Year

Appointments And Advancements

Quarterly Earnings Reports

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026